Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors

• Published in: JCO precision oncology Vol. 8; p. e2300289
• Main Authors: Hu, Yiduo, Narayan, Azeet, Xu, Yunshan, Wolfe, Julia, Vu, Dennis, Trinh, Thi, Kantak, Chaitanya, Ivy, S Percy, Eder, Joseph Paul, Deng, Yanhong, LoRusso, Patricia, Kim, Joseph W, Patel, Abhijit A
• Format: Journal Article
• Language: English
• Published: United States 01.02.2024
• Subjects: Biomarkers, Tumor - genetics; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Circulating Tumor DNA - genetics; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - genetics; Poly(ADP-ribose) Polymerases - therapeutic use; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A - therapeutic use
• ISSN: 2473-4284
• DOI: 10.1200/PO.23.00289

Cell-free circulating tumor DNA (ctDNA) has shown its potential as a quantitative biomarker for longitudinal monitoring of response to anticancer therapies. However, ctDNA dynamics have not been studied in patients with heavily pretreated, advanced solid tumors, for whom therapeutic responses can be weak. We investigated whether changes in ctDNA could predict clinical outcomes in such a cohort treated with combined poly(ADP-ribose) polymerase/vascular endothelial growth factor receptor inhibitor therapy. Patients with metastatic pancreatic ductal adenocarcinoma (PDAC), triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), or non-small-cell lung cancer (NSCLC) received up to 7 days of cediranib 30 mg orally once daily monotherapy lead-in followed by addition of olaparib 200 mg orally twice daily. Patients had progressed on a median of three previous lines of therapy. Plasma samples were collected before and after cediranib monotherapy lead-in and on combination therapy at 7 days, 28 days, and every 28 days thereafter. ctDNA was quantified from plasma samples using a multigene mutation-based assay. Radiographic assessment was performed every 8 weeks. ctDNA measurements were evaluable in 63 patients. The median baseline ctDNA variant allele fractions (VAFs) were 20%, 28%, 27%, and 34% for PDAC, TNBC, SCLC, and NSCLC, respectively. No association was observed between baseline VAF and radiographic response, progression-free survival, or overall survival (OS). Similarly, no association was found between ctDNA decline and radiographic response or survival. However, an increase in ctDNA at 56 days of combination therapy was associated with disease progression and inferior OS in a landmark analysis. ctDNA levels or dynamics did not correlate with radiographic response or survival outcomes in patients with advanced metastatic malignancies treated with olaparib and cediranib.